Latest Melanotan II Stories
CRANBURY, N.J., June 28, 2011 /PRNewswire/ -- Palatin Technologies, Inc.
CRANBURY, N.J., June 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications, announced presentation and publication of a report on validation of a scale for subjective male sexual arousal.
CRANBURY, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction.
CRANBURY, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc.
The U.S. Food and Drug Administration warned consumers about using Melanotan II , which is sold as a skin cancer preventative and tanning agent. The FDA announced Wednesday it had issued a warning letter to the product's manufacturer, Melanocorp Inc.
- In dressmaking, straps running from the belt in front over the shoulders to the belt in the back, with more or less elaboration of trimming and outline. They usually broaden at the shoulder and narrow toward the waist.